Option Care Health (NASDAQ:OPCH) Director Purchases $783,820.10 in Stock

Key Points

• Director Harry Jansen Kraemer, Jr. bought 36,610 shares on May 4 at an average price of $21.41 for a total of $783,820.10, raising his stake to 450,000 shares (an 8.86% increase) valued at about $9.63 million.
• Option Care reported Q1 EPS of $0.40 vs. a $0.37 consensus (beating estimates) while revenue was $1.35 billion versus a $1.39 billion estimate, and the company set FY 2026 guidance at $1.820–$1.920 EPS.
• The stock traded around $21.30 (up 0.8%) on heavy volume (~6.4M vs. a 2.19M average), has a market cap of $3.34 billion and a 52-week range of $18.01–$36.80, and carries a consensus Moderate Buy with an average target of $32.08 while institutional investors own about 98.05% of shares.

Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) Director Harry Jansen Kraemer, Jr. purchased 36,610 shares of the business's stock in a transaction on Monday, May 4th. The shares were bought at an average price of $21.41 per share, with a total value of $783,820.10. Following the purchase, the director directly owned 450,000 shares in the company, valued at approximately $9,634,500. The trade was a 8.86% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Option Care Health Stock Up 0.8%

OPCH stock traded up $0.16 during mid-day trading on Tuesday, reaching $21.30. 6,402,061 shares of the company traded hands, compared to its average volume of 2,190,877. The stock has a market cap of $3.34 billion, a price-to-earnings ratio of 16.51, a P/E/G ratio of 1.12 and a beta of 0.68. The company has a quick ratio of 1.07, a current ratio of 1.64 and a debt-to-equity ratio of 0.85. Option Care Health, Inc. has a fifty-two week low of $18.01 and a fifty-two week high of $36.80. The firm's 50 day moving average price is $29.15 and its 200 day moving average price is $30.74.

Option Care Health (NASDAQ:OPCH - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.37 by $0.03. Option Care Health had a return on equity of 18.17% and a net margin of 3.64%.The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.39 billion. During the same quarter in the previous year, the business earned $0.40 EPS. The company's quarterly revenue was up 1.3% on a year-over-year basis. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. As a group, equities research analysts predict that Option Care Health, Inc. will post 1.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Bank of America cut shares of Option Care Health from a "buy" rating to a "neutral" rating and set a $22.00 target price on the stock. in a research report on Friday. Citigroup reissued an "outperform" rating on shares of Option Care Health in a research report on Tuesday, January 13th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $26.00 target price on shares of Option Care Health in a research report on Friday. Truist Financial set a $30.00 target price on shares of Option Care Health in a research report on Friday. Finally, Wall Street Zen cut shares of Option Care Health from a "buy" rating to a "hold" rating in a research report on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $32.08.

Institutional Investors Weigh In On Option Care Health

A number of hedge funds have recently modified their holdings of the stock. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in shares of Option Care Health by 22.9% in the 1st quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 147,400 shares of the company's stock worth $4,007,000 after purchasing an additional 27,500 shares during the period. State of Michigan Retirement System raised its holdings in shares of Option Care Health by 1.6% in the 1st quarter. State of Michigan Retirement System now owns 38,159 shares of the company's stock worth $1,027,000 after purchasing an additional 600 shares during the period. Principal Financial Group Inc. raised its holdings in shares of Option Care Health by 6.6% in the 1st quarter. Principal Financial Group Inc. now owns 508,426 shares of the company's stock worth $13,687,000 after purchasing an additional 31,574 shares during the period. Fifth Third Bancorp raised its holdings in shares of Option Care Health by 3,855.4% in the 1st quarter. Fifth Third Bancorp now owns 92,082 shares of the company's stock worth $2,479,000 after purchasing an additional 89,754 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Option Care Health in the 1st quarter worth approximately $70,287,000. Institutional investors own 98.05% of the company's stock.

Option Care Health Company Profile

Option Care Health NASDAQ: OPCH is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry's most experienced home infusion businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.